About 40% had a BMI over 40, considered severe obesity. They got either a weekly injection of semaglutide or a placebo for 68 ...

superiority trial designed to evaluate the efficacy of semaglutide 7.2 mg with semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. 1,407 adults with BMI ≥30 kg/m 2 and without ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring thoughts of food.

In general, to qualify for semaglutide, a glucagon-like peptide (GLP-1) drug, individuals must have a: Body mass index (BMI) of 27 or greater, as well as a weight-related health condition ...

Wegovy is another injectable medication made with semaglutide (the active ingredient in Ozempic). It’s approved by the FDA for weight management in people with a body mass index or BMI of 27 who ...

Wegovy contains the drug semaglutide, which is already prescribed on the NHS to help some people with a body-mass index (BMI) above 26 lose weight. And it now becomes the first anti-obesity drug ...